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The anthracycline doxorubicin (DOX) is a potent and
effective antineoplastic antibiotic agent widely used in the
treatment of a broad range of forms of cancer. The clinical
use of DOX is limited by cardiotoxicity, which increases
dose dependently and may lead to dilated cardiomyopathy
and clinical manifestations of congestive heart failure up to
10 to 15 years after the cessation of DOX chemotherapy in
as many as 30% to 40% of patients treated with this drug
(1). It is well established that cardiac oxidative stress from
nicotinamide adenine dinucleotide phosphate oxidases (2)
and mitochondrial sources (3) contributes substantially to
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DOX-associated complications and that early disturbances
in mitochondrial biogenesis and damage of mitochondrial
deoxyribonucleic acid represent other hallmarks of DOX-
mediated cardiotoxicity (4). Notably, a role for oxidative
stress is supported by studies in genetically modified mice
indicating that deficiency of antioxidant enzymes such as
glutathione peroxidase-1, an important hydrogen peroxide–
degrading enzyme, increased susceptibility to DOX-
induced cardiotoxicity (5), whereas overexpression of man-
ganese superoxide dismutase, an essential antioxidant
enzyme in mitochondria, prevented these adverse effects of
DOX (6). In an alternative concept for the mechanism of
DOX-induced cardiotoxicity, independent of oxidative
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they have no relationships to disclose.stress, it was recently hypothesized that DOX-dependent
modulation of the phosphoproteome, cardiac transcriptional
reprogramming, and especially inactivation of adenosine
monophosphate–activated protein kinase (AMPK) and the
creatine kinase, which are 2 key kinases involved in cardiac
energy metabolism (7,8), might play a causal role. Because
many kinases and phosphatases, including AMPK, are
activated or inhibited by reactive oxygen and nitrogen
species, however, these 2 hypotheses should not necessarily
be seen as antagonistic, as low levels of reactive oxygen
species (below the possibility of detection) under long-term
DOX therapy might lead to modifications in the phosphor-
ylation pattern of these enzymes, modulating their kinase
and phosphatase activity.
Improvement of Doxorubicin-Induced
Cardiotoxicity by Inorganic Nitrate Therapy
In this issue of the Journal, Zhu et al. (9) show in an elegant
and convincing way that the coadministration of inorganic
nitrate significantly diminishes DOX-induced cardiotoxicity
and associated cardiomyopathy in an experimental animal
model, as demonstrated by reduced impairment in ejection
fraction and fractional shortening. Furthermore, inorganic
nitrate therapy was associated with lesser changes in systolic
pressure, parameters of systolic and diastolic dysfunction, heart
rate, mean aortic blood pressure, and end-diastolic pressure in
DOX-treated animals. As expected, nitrate therapy increased
the plasma levels of nitrate, nitrite, and nitric oxide (NO)
products (including nitrosyl-iron species and nitrosothiols), a
feature that was interestingly shared by DOX treatment.
However, combination of both treatments was not additive
with respect to nitrate and NO product levels, while nitrite
plasma levels were actually lower in animals treated with nitrate
and DOX compared with those treated with nitrate alone.
Inorganic nitrate therapy almost completely prevented
DOX-mediated cardiomyocyte necrosis (on trypan blue
staining), and cardiomyocyte apoptosis (on terminal deoxy-
nucleotidyl transferase deoxyuridine triphosphate nick end
labeling assay) induction was partially reduced in the nitrate 
DOX group, while the function of mitochondrial complex I
(but not complex II) of the respiratory chain was largely
impaired by DOX treatment and normalized by nitrate
therapy. In accordance with the oxidative stress concept of
DOX-induced cardiotoxicity, the level of cardiac lipid per-
oxidation (malondialdehyde and 4-hydroxynonenal) was dra-
matically increased by DOX treatment and normalized by
nitrate therapy. Besides these fascinating data, another
major advance of the study is that 2 different administration
routes for the inorganic nitrate were tested, namely, oral
administration in drinking water and subcutaneous infusion
by osmotic minipumps using similar doses. Although sub-
cutaneous therapy with inorganic nitrate increased plasma
nitrate levels to a similar extent compared with oral nitrate
administration, there was no increase in plasma nitrite levels
and only minor effects on cardiac function in response to DOX
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with inorganic nitrate had protective effects appears to indicate
that bioconversion by microorganisms in the mouth and/or the
gastrointestinal tract is required for the cardioprotective effects
of inorganic nitrate.
Bioactivation of Inorganic Nitrate
and Nitrite to Vasodilatory Species
There is growing evidence for the beneficial effects of
inorganic nitrate and nitrite therapy on cardiovascular dis-
eases and complications (10). Most of these studies support
the concept that a bioactivation of the inorganic nitrate to
nitrite, which is more easily converted to the vasodilator NO
or a related species (e.g., nitrosothiols) by deoxygenated
hemoglobin (11,12) or in an acidic milieu (e.g., in the
stomach or in the mitochondrial intermembrane space), is
required. Because inorganic nitrate is an inert compound, its
reduction to nitrite is not easily performed by many enzy-
matic systems (13–15). It is well established that microor-
ganisms such as bacteria and fungi display enzymatic activ-
ities reducing inorganic nitrate, leading to its effects on
blood pressure and platelet function in different systems and
models (16). For mammalian tissues or homogenates, a
nitrate-reducing activity has been postulated for several
years. In 2008, xanthine oxidoreductase was identified as a
nitrate-reducing enzyme in vitro, ex vivo, and in vivo (17).
However, to what extent the bacterial and mammalian
pathways contribute to the overall conversion of inorganic
nitrate to nitrite, and subsequently to the bioactivation of
nitrite to the vasodilator NO, has not been investigated so
far (Fig. 1). In the present study, the evidence that despite
the similar plasma nitrate levels obtained via the 2 separate
administration routes, only the oral treatment resulted in an
appreciable improvement of cardiac function under DOX
therapy supports the concept that a gastrointestinal bioac-
tivation of nitrate is a necessary step. Future studies should
further elucidate the importance of both bioactivation path-
ways for the cardiovascular protective effects of inorganic
nitrate therapy. Because treatment with the xanthine oxi-
doreductase inhibitor allopurinol per se displays beneficial
effects in cardiovascular disease, this intervention cannot be
used to investigate the contribution of this enzyme to the
bioactivation of inorganic nitrate. However, the fact that
tungsten treatment leads to replacement of the molybdenum
in xanthine oxidoreductase and results in an inactive enzyme
suggests a possible strategy to investigate this issue.
Is Nitrite and Nitrate Treatment the Next-Generation
Therapy for Cardiovascular Diseases?
A highly protective profile of dietary inorganic nitrate, as
demonstrated by reductions of mean arterial pressure, renal
function, cardiac hypertrophy, and fibrosis as well as by the
normalization of oxidative stress markers (asymmetric di-
methylarginine, malondialdehyde, isoprostane, and 8-oxo-
deoxyguanosin) has been described in salt-induced hyper-tension (18). Very similar protective effects were reported
for endothelial NO synthase knockout mice displaying
features of metabolic syndrome and receiving inorganic
nitrate therapy (19). In this model, inorganic nitrate lead to
decreases in triglycerides, visceral fat, blood glucose, and
glycosylated hemoglobin and to an increase in insulin
production. Furthermore, another battlefield for inorganic
nitrate and nitrite therapy may be, for example, the preven-
tion of ischemia-reperfusion injury (10,20).
Remaining Pieces in the Puzzle
Although the concept that inorganic nitrate and nitrite may
mediate cardiovascular protection is quite attractive, there
are still some caveats and open questions. Nitrite is a very
weak activator of recombinant soluble guanylyl cyclase in
the presence of mitochondria (21). The required concentra-
tion for maximal activation of the purified soluble guanylyl
cyclase was 1 mol/l for the direct NO donor diethylamine
ONOate and 10 mmol/l for nitrite. Moreover, it is known
hat inorganic nitrate but also nitrite are very weak vasodi-
ators in isolated aortic ring segments. Therefore, it is hard
o understand how a 2-fold change in plasma nitrite levels
an be responsible for such a dramatic change in NO levels
n the present animal model.
Another drawback could be the formation of nitro-
amines in response to oral inorganic nitrate and to a much
igher extent oral inorganic nitrite therapy (13,14), which
re known potent inducers of cancer. This side effect could
e avoided by nonoral administration routes of inorganic
itrate and nitrite. However, because the study of Zhu et al.
9) provides good evidence that nonoral therapy may be less
fficient (or even devoid of beneficial effects), another future
hallenge could be to identify new routes for the delivery of
norganic nitrate and nitrite that are safe yet effective.
ethemoglobinemia formation may also represent another
mportant side effect of inorganic nitrate and nitrite therapy,
hich can probably only be avoided by an optimal dosing
egimen (13).
Perspectives
The results presented in this issue of the Journal provide a
new attractive hypothesis for DOX toxicity based on the
observation that DOX treatment increases 4-hydroxynonenal, a
toxic aldehyde (6). This concept is supported by our own
observations that mice with homozygous deficiency in
mitochondrial aldehyde dehydrogenase-2 (ALDH-2) are
more susceptible to DOX-induced cardiac and vascular
damage (22). Noting that ALDH-2 catalyzes the detoxifi-
cation of 4-hydroxynonenal (Fig. 1), inhibition of this
enzyme would result in a deleterious feedback mechanism.
Considering the recent findings on increased susceptibility
of ALDH-2–deficient mice to ischemic damage in experi-
mental myocardial infarction and inactivation of AMPK by
4-hydroxynonenal (23), there seems to be an important link
between the observations on DOX-induced AMPK inacti-
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protective effects of inorganic nitrate and nitrite in
ischemia-reperfusion models. Zhu et al. (9) provide clear
evidence that inorganic nitrate prevents mitochondrial dys-
function and mitochondrial oxidative stress, which provides
a mechanistic background to the beneficial effects of inor-
ganic nitrate on DOX-induced cardiotoxicity observed in
previous reports. In addition, NO, a major mediator of the
beneficial effects of inorganic nitrate, plays an important role
in ischemic pre-conditioning, an important protective
mechanism in which mitochondrial pathways play a crucial
role. Taking into account all of these observations, it is
recommended to explore the effects of inorganic nitrate and
nitrite on mitochondria in more detail and to explore the
role of the mitochondrial protein ALDH-2 as well as the
AMPK, which contributes to regulation of mitochondrial
Figure 1 Metabolic Pathways of Nitrite and Nitrate
Affecting Doxorubicin-Induced Cardiotoxicity
In the oral cavity, the bioactivation of the more stable nitrate (NO3
) to nitrite
(NO2
) requires an initial reduction process by symbiotic bacteria and by the
gastric mucosa (and, according to recent reports, also by xanthine oxidoreduc-
tase). Nitrite, in turn, can be further reduced to nitric oxide (NO) within mito-
chondria by components of the respiratory chain, by acidic disproportionation in
the stomach, or in the intermembrane space of mitochondria or by the xan-
thine oxidoreductase (e.g., under the condition of hypoxia leading to vasodila-
tion and accordingly blood pressure reduction). It should be noted that nitrate
infusion in the study by Zhu et al. (9) had no protective effects. Doxorubicin
(DOX) treatment causes a cardiomyopathy characterized by systolic and dia-
stolic dysfunction, increased mitochondrial damage and formation of oxygen-
derived free radicals, and increased lipid peroxidation with enhanced formation
of toxic products such as malondialdehyde and 4-hydroxynonenal (4HNE).
Nitrate therapy reversed all of these abnormalities and reduced cardiomyocytic
necrotic and apoptotic cell death. It is also likely that some of the beneficial
effects of nitrate therapy involves an activation of protective enzymes such as
aldehyde dehydrogenase-2 (ALDH-2) and adenosine monophosphate-activated
protein kinase (AMPK). mtROS  mitochondrial reactive oxygen species.biogenesis and energy metabolism. The concept of NO-
mediated protective effects of inorganic nitrate and nitrite
may not be as simple as postulated in most of the previous
publications on this topic, because classic NO donors (e.g.,
NONOates, sodium nitroprusside) do not possess similar
beneficial properties, especially under long-term therapy.
There is a great need for clinical proof of effectiveness of
these therapeutic interventions in humans, which should be
based on large outcome-directed clinical trials. If these trials
are successful and prove the effectiveness of inorganic nitrate
and nitrite therapy in various cardiovascular complications,
this would offer a new window for cheap and affordable
cardiovascular therapy for everyone, a highly desirable
result.
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